drugset / Trial / NCT06117306
MDMA-assisted Massed Prolonged Exposure for PTSD
Phase 3
Recruiting
20 enrolled
Healing Breakthrough
National Center for PTSD · collabResilient Pharmaceuticals · collabSan Diego Veterans Healthcare System · collabWhite River Junction VA Medical Center · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The overall objective of this study is to pilot the VASDHS-adapted Emory MDMA-PE Protocol (aE-MDMA-PE) and assess the effect on clinician-rated PTSD symptoms in veterans who receive different doses of MDMA.
Timeline
- Start
- 2024-10-25
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midomafetamine | Unknown | — | — |